Minimal clinically important worsening on the progressive supranuclear Palsy Rating Scale.

about

Minimal clinically important difference of voice handicap index-10 in vocal fold paralysis.CSF neurofilament light chain and phosphorylated tau 181 predict disease progression in PSP.Rating Scales for Movement Disorders With Sleep Disturbances: A Narrative Review.

P2860

Q47793885-008232BA-7C2C-4F49-A8FD-726C0B7AF609 Q47893422-16411890-DD50-4E0D-AD36-078DF43D1CE0 Q55283577-2EB59039-60DA-46C9-8069-9AA67798AA8E

P2860

Minimal clinically important worsening on the progressive supranuclear Palsy Rating Scale.

Item

http://www.wikidata.org/entity/Q39669156

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Minimal clinically important w ...... pranuclear Palsy Rating Scale.

@en

Minimal clinically important w ...... pranuclear Palsy Rating Scale.

@nl

type

Item

label

Minimal clinically important w ...... pranuclear Palsy Rating Scale.

@en

Minimal clinically important w ...... pranuclear Palsy Rating Scale.

@nl

prefLabel

Minimal clinically important w ...... pranuclear Palsy Rating Scale.

@en

Minimal clinically important w ...... pranuclear Palsy Rating Scale.

@nl

P1476

Minimal clinically important w ...... pranuclear Palsy Rating Scale.

@en

P2093

AL-108-231 Investigators

http://www.w3.org/2001/XMLSchema#string

Eldho Paul

http://www.w3.org/2001/XMLSchema#string

Sarah Hewer

http://www.w3.org/2001/XMLSchema#string

Sue Varley

http://www.w3.org/2001/XMLSchema#string

P2860

Davunetide in patients with progressive supranuclear palsy: a randomised, double-blind, placebo-controlled phase 2/3 trial

Behavioral abnormalities in progressive supranuclear palsy.

Power calculations and placebo effect for future clinical trials in progressive supranuclear palsy.

Rate of decline in progressive supranuclear palsy.

Randomized placebo-controlled trial of donepezil in patients with progressive supranuclear palsy.

Determination of minimal clinically important change in early and advanced Parkinson's disease.

Short-term effects of coenzyme Q10 in progressive supranuclear palsy: a randomized, placebo-controlled trial.

A clinical rating scale for progressive supranuclear palsy.

Characterizing behavioral and cognitive dysexecutive changes in progressive supranuclear palsy.

A phase 2 trial of the GSK-3 inhibitor tideglusib in progressive supranuclear palsy.

P304

1574-1577

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/MDS.26694

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

David R. Williams

Adam L Boxer

P577

2016-06-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27324431

http://www.w3.org/2001/XMLSchema#string

P932

5215805

http://www.w3.org/2001/XMLSchema#string

Minimal clinically important worsening on the progressive supranuclear Palsy Rating Scale.

about

P2860

P2860

Minimal clinically important worsening on the progressive supranuclear Palsy Rating Scale.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P932